Podcasts about royalties

Greg Schlaepfer is the founder of Orange Tree Samples, where he's spent seventeen years solving a strange problem: how do you take an instrument with six strings and two hands doing completely different things, and make it playable from a keyboard?We talk about the magic trick that gave the company its name, why he pays royalties to every musician and engineer who works on a library, and what it actually costs to spend eleven years finishing a single project — three scrapped interfaces, several rounds of burnout, and 376 instruments later.Along the way: chasing realism versus loving lo-fi sounds for what they are, why impressing people is the weakest way to move them, and what it means to be an artist on the days you feel like anything but.

**Ever wonder why some artists never see a dime from their hits? Here's the truth about black box royalties...** Drop a

Interview with Drew Clark, President and CEO, Summit RoyaltiesOur previous interview: https://www.cruxinvestor.com/posts/summit-royalties-tsxvsum-targets-15m-revenue-run-rate-with-new-gold-streams-by-2028-10897Recording date: 28th July 2026Summit Royalties has added a new financing tool to a growth strategy that, until now, has relied almost entirely on equity. On July 27, the company announced a credit agreement with National Bank of Canada for a revolving facility with an initial US$25 million commitment, alongside an accordion feature providing for an additional US$25 million on the same terms — for total potential availability of US$50 million. The facility carries a three-year initial tenor, interest priced off SOFR or CORRA plus a leverage-dependent spread of 2.50% to 4.00%, and standard covenants including net leverage, interest coverage, and minimum liquidity requirements.Speaking to Crux Investor's Matt Gordon the day after the announcement, President and CEO Drew Clark was direct about what the debt is for and, just as importantly, what it isn't for. Summit's stated discipline is to use debt only against assets that will generate cash flow within three to five years — a narrower standard than the one that has applied to some of Summit's equity-funded acquisitions, including its recently closed purchase of Star Royalties, which added the Copperstone gold stream in Arizona to Summit's portfolio.Clark also used the interview to correct an earlier public framing of Summit's acquisition discipline. He clarified that roughly $250 million worth of transactions were rejected because Summit's own bids came in below sellers' clearing prices — for example, bidding $65 million on an asset that ultimately cleared at $80 million — rather than Summit walking away from opportunities that met its criteria. It's a useful clarification for investors trying to gauge how aggressively management is actually competing for assets versus how selectively it is declining them.On current market conditions, Clark described deal-making as comparatively easier than during the recent gold price peak, since the gap between long-term and spot pricing has narrowed. He flagged tungsten streams as a specific area of emerging opportunity alongside Summit's core precious metals focus, and noted that Summit is evaluating opportunities as both an acquirer and a potential acquisition target within the sector's ongoing consolidation.The most concrete disclosure for investors may be management's own valuation framework. Clark said the internal belief is that once Summit's revenue reaches somewhere between $20 million and $30 million annually, the company should re-rate toward 1 to 1.2 times NAV — in line with royalty peers — and toward 15-20 times revenue, versus a current multiple he characterised as below 10 times and a NAV multiple around 0.6 times. Management continues to target a production run rate of roughly 4,000 gold-equivalent ounces by the end of 2028 as the operational catalyst behind that thesis.Learn more: https://www.cruxinvestor.com/companies/summit-royaltiesSign up for Crux Investor: https://cruxinvestor.com

Making a Scene Presents - Your Distributor Is Becoming Your Storefront: Private Equity, Consolidation, and the Fight for the Independent Artist's Customer For many independent artists, choosing a music distributor feels like choosing a mailbox. You upload the song, type in the title, attach the artwork, enter enough names and numbers to make your eyes glaze over, and then wait for the music to appear on Spotify, Apple Music, Amazon Music, YouTube Music, TikTok, and the rest of the digital neighborhood. The distributor delivers the package. The stores play the music. Royalties eventually trickle back. Everybody goes home. That simple picture is becoming badly outdated. http://www.makingascene.org

Connor Pugliese, Vice President of Corporate Development for Summit Royalties Ltd. (TSX.V: SUM) (OTCQX: SUMMF), joins us to outline the value proposition from the current portfolio of 48 royalties and streams, but also the ability to grow with future transaction thanks to the announcement of US$50Million revolving credit facility.   On July 27th, the Company reported that it has entered into a credit agreement with National Bank of Canada for a revolving credit facility with an initial commitment of US$25 million. The Facility includes an accordion feature providing for up to an additional US$25 million, subject to the satisfaction or waiver of certain conditions, for total potential availability of US$50 million.   Key terms of the Facility include:   Maturity: The Facility has an initial tenor of three years, with Summit having the right to request an extension of the maturity date, subject to satisfaction or waiver of certain conditions and the consent of the lenders; Purpose: The Facility is available for working capital and other general corporate purposes (including acquisitions permitted under the Facility); Interest rate: Advances bear interest at the Secured Overnight Financing Rate or the Canadian Overnight Repo Rate Average, as applicable, plus a credit spread adjustment depending on the tenor of the applicable loan and 2.50% to 4.00% per annum, depending on the Corporation's net leverage ratio; Standby fee: The undrawn portion of the Facility is subject to a standby fee of 0.5625% to 0.9000% per annum depending on the Corporation's net leverage ratio; Financial covenants: The Facility requires the Corporation to meet certain financial covenants, including a net leverage ratio, an interest coverage ratio and a minimum liquidity amount;   Connor shares his background in the industry have created a number of royalties with Triple Flag PMs where mining companies are given much needed development capital in exchange for a royalty or stream on that project when it goes into production.  We also highlight Drews background making accretive acquisitions on existing 3rd-party royalties and streams. The company will be pursuing both approaches for new transactions with this credit facility.   We review again the growth still available in the existing 4 producing royalties as well as the 2 development-stage royalties moving into initial production by year end but ramping up into commercial production in 2027.  Wrapping up Connor outlines the value proposition for Summit Royalties both in terms of future compounded growth metrics, as well as in comparison to royalty peers in the sector.     Click here to follow the latest news from Summit Royalties   If you have any follow up questions for Connor about Summit Royalties, then please email them into us at Fleck@kereport.com or Shad@kereport.com.   In full disclosure, Shad is a shareholder of Summit Royalties at the time of this recording, and may choose to buy or sell shares at any time.     For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.      

This week, Punter Konrad brings you two massive ideas Australia could implement right now that would make everyone's lives better, cheaper, and fairer, but probably won't happen because the corporate lobbyists and media machine will do everything they can to stop it. We break down why legendary finance journalist Alan Kohler thinks nationalising childcare is the only way to fix the broken system where we subsidise private profits while parents pay exorbitant fees for lower quality care, how economist Cameron Murray explains why a variable royalty on gas that scales with the market price would lock in billions during booms without letting the lobbyists unwind it during busts, and why both of these solutions are common sense until the corporate media gets their filthy mitts on them and turns them into culture war fights to protect billionaire profits over punter wellbeing. Bypass the Algorithm, Sign up to the Punter Times Newsletter https://www.punterspolitics.com/pages/email-sign-up Support We the Punters on PATREON (https://www.patreon.com/punterspolitics) Buy Punters Stickers & T-shirts (https://www.punterspolitics.com/) Learn more about your ad choices. Visit megaphone.fm/adchoices

A new analysis questions whether Saskatchewan is getting a fair return from one of its major potash mines, suggesting K+S paid only a fraction of the value of the resource it extracted in 2025. We'll dig into how potash royalties work—and whether taxpayers are getting the deal they should. Erin Weir, Consulting Economist and Former MP for Regina–Lewvan joins the show.

Making a Scene Presents - AI Training Royalties Are Coming—But Will Indie Artists Get Paid? Artificial intelligence companies have spent the past few years treating music like an unattended buffet. Recordings, lyrics, artwork, voices, performances, and entire creative styles have been pulled into giant data collections. Artists were often left wondering whether their work had been used, who used it, what it helped create, and whether anybody planned to pay them. Now the music business is beginning to move toward a different model. Instead of taking first and arguing about permission later, some companies are trying to build licensed AI systems in which creators can choose whether their work is included. That sounds better. It probably is better. But “better than unpaid scraping” is a pretty low bar. A raccoon with a stolen sandwich could clear it. The real question is not whether AI licensing programs will exist. They are already beginning to appear. The real question is whether independent artists will receive fair payments, useful reports, meaningful control, and enough information to know whether the deal makes sense. There is also another uncomfortable question. When an AI company finally comes looking for licensed music, will the artist be able to prove what they own? http://www.makingascene.org

Grab our breakdown of the 5 Low-Cost Businesses That Make $1 Million: https://www.franchiseempire.com/lowcost?utm_source=fejuly212026This video explores the purpose, structure, and value of franchise royalties from both a franchisee and franchisor perspective. Tariq, Marc and Chris break down how royalties whether percentage-based or flat rates—serve as an investment that allows franchisors to reinvest in systems, technology, and support talent. Additionally, the discussion covers related financial elements like initial franchise fees, minimum monthly royalties, and the contemporary value of digital marketing ad funds.------------------Considering Investing In A Franchise?

Most people have strong opinions about franchising—but how many of those opinions are actually true?   In this episode of Franchise Unfiltered, Wes Barefoot reacts to a podcast criticizing franchising and breaks down where they make valid points... and where they completely miss the mark.   We cover:   -The truth about franchise failure rates -Independent business vs. franchise ownership -Whether franchise fees are actually worth it -Why due diligence matters more than the brand name -The biggest mistakes franchise buyers make -How successful franchise owners really build wealth   If you're considering buying a franchise, this episode could save you from making an expensive mistake.   Timestamps: 00:00 Introduction 01:20 Why people misunderstand franchising 03:00 Franchise failure rates explained 08:00 Are franchise fees worth it? 12:00 What you're actually paying for 17:00 Royalties, profits & common misconceptions 21:00 Should new businesses franchise? 26:00 The truth about failing franchise locations 29:40 How to evaluate a franchise 33:20 Why franchisee validation matters 35:40 Final thoughts   7 Steps to Owning a Franchise: https://path2frdm-1.hubspotpagebuilder.com/path-to-freedom-about-franchising  

This week, we sit down with legendary Australian journalist Ray Martin for a raw, unfiltered conversation about media, power, and whether everyday punters can actually change anything. We break down why corporate media is consolidating while trust is collapsing, how billionaires use newspapers to protect their real businesses, whether the ABC is truly independent or just responding to Murdoch's agenda, and why Ray thinks social media might be better than the old system despite AI and disinformation running rampant. We get into why politicians still suck up to Murdoch even when he attacks them, how gas companies use scare tactics to protect their rip off contracts, whether Aussies are too afraid to challenge authority despite hating tall poppies, and why Ray's advice after 60 years in journalism comes down to three words: have a go. Bypass the Algorithm, Sign up to the Punter Times Newsletter https://www.punterspolitics.com/pages/email-sign-up Support We the Punters on PATREON (https://www.patreon.com/punterspolitics) Buy Punters Stickers & T-shirts (https://www.punterspolitics.com/) Learn more about your ad choices. Visit megaphone.fm/adchoices

Top headlines for Friday, July 10, 2026A Maryland church accused of hiding a cell tower above its preschool, Charlie Kirk's family speaks as his accused killer faces court, a Christian nurse in Britain is cleared after a pronoun dispute, and concerns persist for Christians in China despite a pastor's release.0:11 Lutheran church hiding cell tower antenna above preschool0:58 Erika Kirk speaks out amid hearing in Charlie Kirk murder trial1:47 Christian nurse at center of trans pronouns dispute speaks out2:40 Lecrae opens up about making John Piper 'an idol' in his life3:27 Trump makes over $200K from 'God Bless the USA' Bible in 20254:22 Christians remain threatened in China even after pastor's release5:16 Salvation Army allegedly forced employee with cancer to resignSubscribe to this PodcastApple PodcastsSpotifyGoogle PodcastsOvercastFollow Us on Social Media@ChristianPost on TwitterChristian Post on Facebook@ChristianPostIntl on InstagramSubscribe on YouTubeGet the Edifi AppDownload for iPhoneDownload for AndroidSubscribe to Our NewsletterSubscribe to the Freedom Post, delivered every Monday and ThursdayClick here to get the top headlines delivered to your inbox every morning!Links to the NewsLutheran church hiding cell tower antenna above preschool | U.S.Erika Kirk speaks out amid hearing in Charlie Kirk murder trial | U.S.Christian nurse at center of trans pronouns dispute speaks out | WorldLecrae opens up about making John Piper 'an idol' in his life | EntertainmentTrump makes over $200K from 'God Bless the USA' Bible in 2025 | PoliticsChristians remain threatened in China even after pastor's release | WorldSalvation Army allegedly forced employee with cancer to resign | U.S.

IBM just unveiled NanoStack, its take on the CFET transistor architecture that succeeds gate-all-around as the next step in chip scaling — and it could turn IBM's patent portfolio into a real semiconductor royalty business.IBM claims NanoStack delivers up to a 50% jump in compute performance or a 70% gain in energy efficiency versus its 2021 two-nanometer IP. IBM sold its chip manufacturing business to GlobalFoundries back in 2015, yet it still holds one of the largest patent portfolios in the industry, and IP licensing and custom development income made up nearly 10% of IBM's GAAP net income in 2025. We break down IBM's 2025 revenue, R&D spend, and licensing income, then identify who benefits most across the supply chain, including ASML, Lam Research, Tokyo Electron, and Screen Holdings as advanced lithography, etch, deposition, and wafer-cleaning suppliers to Rapidus, the Japanese foundry startup aiming to ramp production by 2027.This is part of our ongoing coverage of the semiconductor manufacturing supply chain and the next 15 years of chip advancement.Full research is available for members at Semiconductor Insider — join at chipstockinvestor.com.Get 15% off your membership with our link: fiscal.ai/csiContent in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal.

Crise no governo do Estado do Rio de Janeiro e Alerj Eleições a presidente, governador e senador do RJ Violência, dívida com o a união e partilha dos Royalties

The Publishing House Royalties Engine - https://www.marketingsharks.com/the-publishing-house-royalties-engine/The Publishing House Royalties Engine – From Paul Coleman – An Unknown author, we studied the algorithm, and now her entire catalog was acquired for a $38 Million dollar valuation. We have her strategy, we have her prompt, we have everything.From obscurity, to huge visibility, very rapidlyShe studied the Amazon algorithm deeplyShe experimented with a few booksAnd then a short series that made a few dollarsBut then she had a genuine breakthrough…She realized how much the algo loved LONGER seriesSo she designed a ten-book series for the algoIt caught the attention of the algorithm immediatelyAnd Amazon literally did her book promotion for her!Fans responded in a VERY BIG WAYAmazon loved the book, fans loved the bookThe algorithm kept on promoting her bookThe momentum, the royalties went off the chart

Hub Headlines features audio versions of the best commentaries and analysis published daily in The Hub. Enjoy listening to original and provocative takes on the issues that matter while you are on the go.0:22 - The most overlooked aspect of the new West Coast pipeline could be the most consequential, by Jack M. Mintz6:21 - The Carney government's expanding power to identify Canadians online, access their data—and punish them, by Graeme GordonThis program is narrated by automated voices. To get full-length editions of popular Hub podcasts and other great perks, subscribe to the Hub for only $2 a week: https://thehub.ca/join/hero/Subscribe to The Hub's podcast feed to get all our best content:https://tinyurl.com/3a7zpd7e (Apple)https://tinyurl.com/y8akmfn7 (Spotify)xWatch The Hub on YouTube: https://www.youtube.com/@TheHubCanadaThe Hub on X: https://x.com/thehubcanada?lang=enCREDITS:Alisha Rao – Producer & Editor Hosted on Acast. See acast.com/privacy for more information.

Interview with Drew Clark, CEO, Summit RoyaltiesOur previous interview: https://www.cruxinvestor.com/posts/summit-royalties-tsxvsum-new-royalty-player-fills-sub-1b-market-gap-with-accretive-ma-9472Recording date: 29th June 2026Summit Royalties, a newly listed precious metals royalty company led by CEO Drew Clark, has taken a significant step in scaling its business with the acquisition of Star Royalties for approximately CAD $50 million. The transaction adds a high-grade, permitted, and currently under-construction gold stream at the Copperstone project in Arizona, strengthening the company's near-term production profile and shifting its portfolio toward more advanced assets.Following the deal, Summit has doubled its projected cash flow to roughly USD $20 million once all assets reach full production, up from an earlier estimate of $10 million. The company is targeting a production run rate of about 4,000 gold ounces by 2028, which could generate more than USD $15 million in annual revenue at current gold prices. These projections are anchored by two key assets: the Copperstone stream and a royalty linked to a Jaguar Mining project, both operated by well-capitalized, established mining companies. This reduces reliance on speculative development and lowers execution risk compared to early-stage projects.Summit is also evolving its funding strategy. While early growth relied on equity financing, the company is now pursuing a revolving credit facility with a major bank, enabling it to use debt alongside equity to fund future acquisitions and potentially limit shareholder dilution.Management emphasizes disciplined growth, noting that over USD $250 million in potential deals have been reviewed and rejected to maintain quality and value. Insider ownership stands at approximately 12%, aligning management with shareholders.Overall, Summit Royalties is positioning itself as a rapidly growing but selective player in the royalty sector, focusing on low-risk, near-term production assets while expanding its financial flexibility to support continued portfolio growth.Learn more: https://www.cruxinvestor.com/companies/summit-royaltiesSign up for Crux Investor: https://cruxinvestor.com

Drew Clark, President and CEO of Summit Royalties Ltd. (TSX.V: SUM) (OTCQX: SUMMF), joins me to outline the transformational acquisition of Star Royalties Ltd. (TSXV: STRR, OTCQX: STRFF), which closed on July 3rd, 2026. The Arrangement materially expands Summit's portfolio with the addition of Star's royalty and streaming interests, including a 4% gold stream on Mining Americas Inc.'s (formerly Minera Alamos Inc.) Copperstone Project in Arizona.   The Copperstone gold stream provides Summit Royalties with exposure to a fully permitted Arizona gold development project where Mining Americas recently announced a positive pre-feasibility study and a formal construction decision. Based on the PFS results and current estimates, project construction is expected to take approximately one year, with initial production of 46,000 oz of gold per year anticipated by mid-2027.   Drew highlighted the upside potential to continue to grow the underground resources of the Copperstone Mine, considering Mining Americas having just announced a planned increase in the mill throughput from 600tpd to 1000tpd. Additionally, Mining Americas just announced there is a portion of resources outside of the PFS that exist in near-surface areas in proximity to the historic open pit excavations, and the Company believes there is potential for gold mineralization to be extracted via open pit mining methods.  This open pit was not even factored in the initial valuation process, and Drew mentioned it was now like getting a gold stream on 2 mines for the price of 1.     Together with their existing portfolio, including a royalty on Jaguar Mining's near-term producing Pitangui Project, where development is expected to commence in 2026 with first gold production targeted in 2027, this acquisition transaction of the gold stream on Copperstone strengthens the Company's future revenue and cash flow growth.     With the closing of the Arrangement, Summit's portfolio now includes 48 royalties and streams, anchored with four producing assets, two assets expected to enter construction in 2026 which are targeted to begin production in 2027, and 42 additional royalties expected to add additional cash flow growth and optionality for years to come.  The portfolio is focused mostly on gold and silver, and spans across 3 core jurisdictions - Canada, USA, and Australia.  Summit is now the fastest growing company in the precious metals royalty sector; having completed their first royalty and stream transaction in May 2025, and just went public in the 2nd half of last year.     Summit Royalties has continued to demonstrate its ability to identify and execute accretive transactions, and intends to build on that momentum with discipline, to become the next mid-tier streaming and royalty company.  Drew outlines that they are reviewing a few key term-sheets to keep making future actionable and accretive acquisitions to increase production and cash flow growth. Improved capital markets presence and trading liquidity, with supportive shareholder base. Pro forma Summit valued at a significant discount to peers on Price/NAV and Price/2027E cash flow per share (“CFPS”) basis. The Corporation currently has no debt and sufficient cash on-hand for use in future acquisitions, as well as being in dialogue with financial institutions for adding a potential revolving credit facility.     If you have any follow up questions for Drew about Summit Royalties, then please email them into me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Summit Royalties at the time of this recording, and may choose to buy or sell shares at any time.   Click here to follow the latest news from Summit Royalties   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.    

As if we'd pass up the chance to talk with Clueless writer and director Amy Heckerling! We're delighted to share this conversation about the making of her totally awesome adaptation of Emma. In this episode, Amy takes us behind the scenes to discuss how she reimagined Austen's novel for contemporary Beverly Hills—from the film's characters and plot to its casting, costumes, distinctive visual style, memorable soundtrack, and now-iconic Clueless lexicon. She also reflects on her experience as a female filmmaker and the creative choices that helped make Clueless a modern classic.(This conversation was recorded during JASNA's members-only Clueless watch party, held in celebration of the film's 30th anniversary in July 2025.)Amy Heckerling is an acclaimed writer, director, and producer whose work spans film, television, and theater. In addition to writing and directing the Clueless, she also wrote and directed Look Who's Talking, Look Who's Talking Too, Loser, I Could Never Be Your Woman, and Vamps. Her directing credits include Fast Times at Ridgemont High, Johnny Dangerously, and National Lampoon's European Vacation, and she produced A Night at the Roxbury. Amy's television work has included executive producing, writing, and directing episodes for the series Clueless and Fast Times, and directing episodes of The Office, Gossip Girl, The Carrie Diaries, Red Oaks, Weird City, and Royalties.  Amy also wrote the script for Clueless, The Musical, which opened at London's Trafalgar Theatre in the West End in March 2025.For an edited transcript and show notes, visit https://jasna.org/austen/podcast/ep37*********Visit our website: www.jasna.orgFollow us on Instagram and FacebookSubscribe to the podcast on our YouTube channelEmail: podcast@jasna.org

Voor wie dacht dat Nike nu eindelijk met goed nieuws zou komen, zat mis. Het herstel (waar beleggers al jaren op wachten) laat nóg langer op zich wachten. Dat is de conclusie na het zien van de kwartaalcijfers. Vooral China springt eruit: de omzetdaling wordt daar alleen maar erger. Je raadt het dus al: de vooruitblik ziet er niet goed uit. De komende zes maanden zullen de omstandigheden niet verbeteren, denkt de directie. Deze aflevering kijken we of er nog lichtpuntjes in de cijfers vindbaar zijn. Wat voor jou als aandeelhouder (of potentiële aandeelhouder) het houvast is in deze resultaten. En wanneer dan ein-de-lijk dat herstel gaat plaatsvinden. Hoor je ook alles over de plannen van Basic-Fit. Dat heeft namelijk wéér een bedrijf overgenomen. Dit keer een in Duitsland. We kijken of de fitnessketen nu ook zelf breder wordt en of ze het aandeel meer gaan oppompen. Het aandeel Meta wordt ook opgepompt. Je hoort waarom het aandeel even 10 procent (!) in de plus staat. Praten we je ook bij over de crypto-inkomsten van president Trump. Die heeft even een miljard dollar verdiend met zijn belangen in de digitale munt. En Maxim heeft een prachtig verhaal over de gekke hobby van Mark Zuckerberg. Te gast: Thomas Pellegrom van ABN Amro MeesPierson BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. See omnystudio.com/listener for privacy information.

Europe is boiling, a shaky ceasefire between Iran and the US, a push for newables and questions around the future of oil. What's the outlook for this province and are we ready if royalties plummet?

Click here to join Sync Producer Hub Highlights from a live Sync Producer Hub episode: members celebrate placements and licensing wins, share practical advice on pitching the same playlist to multiple libraries, and explain delivery details (stems, cutdowns, sample rates). The episode also breaks down mechanical vs performance royalties and how reruns keep paying, discusses tools like session player, AI artwork, Disco/Co-Work automation, and publishers' preferences, and answers community questions on starting a publishing admin and using AI in submissions.

Welcome back to When Words Fail, Music Speaks, the podcast that explores how music can lift us out of the darkness and into hope. I'm your host, James Cox, a lifelong fan‑turned‑handicapped host who's learned to lean on riffs, verses, and relentless head‑banging whenever life gets heavy.In today's episode we sit down with none other than Jack Owen, the lead guitarist behind Six Feet Under and a longtime contributor to Cannibal Corpse. Jack walks us through everything from the day‑to‑day grind of living with depression to why his doctor says he can drink all the coffee he wants. We dig into the nitty‑gritty of royalty disputes—remember the DSI arranging‑credit debacle?—and the importance of getting proper credit, especially in a genre that's notorious for keeping the spotlight on the front‑man.Jack also shares his evolution from six‑string to seven‑string guitars, the challenges of muting low D notes, and how that extra string opened up a whole new low‑end for Cannibal Corpse's brutal sound. We get an inside look at the making of the “Mr. Blood and Guts” video—its silent‑film, 1930s‑style horror vibe, and the campy “Phantom of the Opera” storyline that inspired the lyrics.The conversation then shifts to songwriting. Jack explains how he still leans on classic verse‑chorus‑bridge structures, how he transforms fast riffs into crushing breakdowns, and why harmonic minor has become his go‑to scale to give those “evil” pentatonic flavors. We also hear his thoughts on legacy—seeing newer bands borrow Cannibal‑style pull‑offs, the honor (and occasional cringe) of inspiring the next generation, and the ever‑changing landscape of metal media from glossy magazines to today's digital hustle.Finally, we touch on life on the road in 2026: touring logistics, the struggle with promoters who pay you in pasta, the simple joy of wandering a new city after a show, and the plan to meet up at the upcoming Chapel of Bones gig in July.Grab your headphones, crank the volume, and get ready for a candid, riff‑filled deep‑dive with one of death metal's most underrated architects. When words fail, Jack's guitars—and his stories—let the music speak.

Michael Iannuzzi, Partner and Franchise Practice Leader at Citrin Cooperman, joins host Brendon Dennewill to unpack the financial and operational fault lines that quietly derail growing franchise systems. From the tension between top-line and bottom-line incentives to the infamous "100-unit ceiling," Michael brings a practitioner's lens to unit economics, royalty self-sufficiency, and the decisions leaders delay until it's too late. If you're scaling a franchise brand and wondering when to rebuild your systems, hire your next leader, or fire yourself from your current role, this episode delivers the framework.What You'll LearnWhy franchisors and franchisees have competing financial interestsThe metric that signals when real growth beginsWhat the "100-unit ceiling" looks like in practiceWhen to fire yourself as a founderHow to build a tech stack from day oneWhat private equity actually looks for in a franchise systemThe rule of threes and tens in franchise growthResources MentionedIFA (International Franchise Association)Restaurant Leadership Conference  Franchise and Fitness Conference (Chicago) Citrin Cooperman Franchise Practice QuickBooks / XERO  FDD (Franchise Disclosure Document) Franchisee Advisory Council (FAC) The Rule of Threes and Tens - Growth framework referenced by CEO of Rakuten Is your business ready to scale? Take the Growth Readiness Score to find out. In 5 minutes, you'll see: Benchmark data showing how you stack up to other organizationsA clear view of your operational maturity Whether your business is ready to scale (and what to do next if it's not)Let's ConnectSubscribe to the RevOps Champions NewsletterLinkedInYouTubeExplore the show at revopschampions.com. Ready to unite your teams with RevOps strategies that eliminate costly silos and drive growth? Let's talk!

Hosts Tait Duryea and Ryan Gibson sit down with Elena Melchert to examine how energy demand, fossil fuels, mineral rights, royalties, and infrastructure shape real passive income opportunities. Elena brings a grounded, technical perspective to a sector many investors hear about but rarely understand deeply. For pilots and high-income professionals looking at alternative investments, tax strategy, and long-term cash flow, this conversation offers a clearer way to think about energy as both a global necessity and a potential portfolio play.Elena Subia Melchert is the founder and president of Energia Consulting LLC and host of Oil and Gas Upstream. With a career spanning engineering, energy technology, federal policy, and industry advisory work, Elena helps connect technical expertise with practical energy solutions. Her background includes leadership in upstream research at the U.S. Department of Energy, along with ongoing work in emerging energy areas such as geothermal, carbon storage, produced water, and geologic hydrogen. She brings rare depth, clarity, and real-world perspective to today's energy conversation.Show notes:(0:00) Intro(2:17) Elena's oil and gas background(7:31) Upstream research and technology(10:06) The reality of energy transition(16:28) Energy poverty around the world(18:42) Pilots, fuel costs, and investing(20:42) Fossil fuels over the next 50 years(22:19) Infrastructure versus production(25:41) How oil and gas royalties work(30:32) Royalties during market downturns(40:13) Geothermal and critical minerals(43:28) OutroConnect with Elena Melchert:Website: https://energiaconsultingllc.com/our-company LinkedIn: https://www.linkedin.com/in/elenamelchert/ Podcast: https://podcasts.apple.com/us/podcast/oil-and-gas-upstream/id1450833136 If you're interested in participating, the latest institutional-quality self-storage portfolio is available for investment now at: https://turbinecap.investnext.com/portal/offerings/8449/houston-storage/ — You've found the number one resource for financial education for aviators! Please consider leaving a rating and sharing this podcast with your colleagues in the aviation community, as it can serve as a valuable resource for all those involved in the industry.Remember to subscribe for more insights at PassiveIncomePilots.com! https://passiveincomepilots.com/ Join our growing community on Facebook: https://www.facebook.com/groups/passivepilotsCheck us out on Instagram @PassiveIncomePilots: https://www.instagram.com/passiveincomepilots/Follow us on X @IncomePilots: https://twitter.com/IncomePilotsGet our updates on LinkedIn: https://www.linkedin.com/company/passive-income-pilots/Do you have questions or want to discuss this episode? Contact us at ask@passiveincomepilots.com See you at the next one!*Legal Disclaimer*The content of this podcast is provided solely for educational and informational purposes. The views and opinions expressed are those of the hosts, Tait Duryea and Ryan Gibson, and do not reflect those of any organization they are associated with, including Turbine Capital or Spartan Investment Group. The opinions of our guests are their own and should not be construed as financial advice. This podcast does not offer tax, legal, or investment advice. Listeners are advised to consult with their own legal or financial counsel and to conduct their own due diligence before making any financial decisions.

This week on the New Music Business podcast, Ari sits down with Eliah Seton, CEO of SoundCloud. Eliah breaks down how SoundCloud is evolving beyond streaming into a creator-first platform focused on fan relationships, monetization, and artist discovery.Why “streaming is not enough” for artists, how fan-powered royalties work, the future of direct-to-fan monetization, and why creator tools are becoming more important in the AI era. Eliah also explains SoundCloud's approach to generative AI music, ethically trained AI models, and why the platform refuses to monetize fully AI-generated songs.Follow Eliah Seton and SoundCloud:Instagram: https://www.instagram.com/eliahseton/https://soundcloud.com/Check out Ari's Take:https://aristake.com08:27 - Eliah Seton on the Future of SoundCloud13:41 - Why “Streaming Is Not Enough” for Artists18:15 - Fan Monetization, Merch, and Direct-to-Artist Revenue22:03 - How SoundCloud Helps Artists Get Heard and Build Fans27:14 - Creator Subscriptions and Fan-Powered Features31:24 - Wallets, Tipping, and the Future of Fan Transactions36:01 - AI Tools for Music Creation and Artist Discovery40:48 - SoundCloud's Approach to Ethically Trained AI47:17 - AI Music, Royalties, and Streaming Economics52:08 - The Future of Human Artistry in the AI EraEdited and mixed by Ruben ZarateMusic by Brassroots DistrictProduced by the team at Ari's TakeOrder the THIRD EDITION of How to Make It in the New Music Business: https://book.aristake.com Hosted on Acast. See acast.com/privacy for more information.

What happens to African creative workers after the contract is signed and the camera stops rolling? In Episode 142, filmmaker Mr Takunda joins IP Series for an unflinching conversation about who really owns African film and who profits from it.From buy-out clauses that strip writers and directors of long-term earnings, to the collapse of major streaming platforms and what that means for content catalogues, this episode covers the conversations the industry avoids having in public.Topics include: why African licensing deals are rarely revenue-sharing; what rights filmmakers surrender to streamers and investors; whether African actors will ever see Hollywood-style residuals; the Showmax restructuring and its IP implications; and what a fairer system for African creatives would actually require.If you create, invest in, or care about African storytelling, this episode is a must listen.Subscribe to IPSERIES for conversations at the intersection of intellectual property and the real world.Thank you for listening, and see you next time on the IP Series podcast!LinkedIn: Takunda Aaron (Zen ISA) Chimutashu=================================IPSERIES PODCAST- Facebook: https://web.facebook.com/groups/836484013662125/- Instagram: ⁠Instagram⁠- Email: ipseriesinfo@gmail.com=================================SOCIAL MEDIA BY: Rita Anwiri Chindah=================================LOGO DESIGN BY: Rita Anwiri Chindah ⁠ipseries_with_reedah | Twitter, Instagram, Facebook | https://linktr.ee/ipseries_with_reedah?subscribe

Estate planning often becomes far more difficult when families inherit assets tied to royalties, licensing rights and public image. Clear communication and preparation can make the difference between unity and conflict after a loved one passes away. In this episode of Celebrity Estates, Senior Editor David Lenok speaks with Scott Rahn, trust and estates litigator and founding partner of RMO LLP, about the estate of Chuck Norris and the planning considerations tied to celebrity wealth. Using Norris' reported $70 million estate as a framework, Scott explains why celebrity net worth figures often differ from the actual value of an estate, particularly when royalties, private companies and likeness rights are involved. David and Scott also explore the importance of family communication, the responsibilities that come with fiduciary roles, and why coordinated advisory teams can help reduce disputes after a death occurs. Their conversation highlights how preparation, flexibility and clear expectations can help families better manage both the emotional and financial realities of complex estates. Key takeaways: Why celebrity estate valuations often shift dramatically based on royalties, public image and timing How family expectations can create tension when emotional value differs from economic value Why heirs inheriting IP rights face responsibilities beyond simply receiving money or property How coordinated advisors and family communication can reduce disputes after a death occurs Why estate plans should allow flexibility as family structures and financial realities evolve Resources: Listen to Celebrity Estates on Wealth Management Subscribe and listen to Celebrity Estates on Apple Podcasts Subscribe and listen to Celebrity Estates on Spotify Trust and Estates Magazine Connect With David Lenok: david.lenok@informa.com  Wealth Management LinkedIn: David Lenok LinkedIn: Informa LinkedIn: Wealth Management Connect With Scott Rahn: LinkedIn: Scott Rahn LinkedIn: RMO Lawyers Website: RMO Lawyers Email: rahns@rmolawyers.com  About Our Guest: Los Angeles attorney Scott Rahn resolves contests, disputes, and litigation related to trusts, estates, and conservatorships, creating a welcome peace of mind for clients.  He represents heirs, beneficiaries, trustees, and executors.  He utilizes his experience to develop and implement strategies that swiftly and cost-effectively address the financial issues, fiduciary duties, and emotional complexities underlying trust contests, estate conflicts, and probate litigation. Driven by a commitment to provide relief to people grieving the loss of a loved one, Scott collaborates closely with clients. He pursues and defends claims involving incapacity, incompetence, undue influence, breach of fiduciary duty, and other similar areas of dispute.  His advice and counsel include prevention and remediation of financial elder abuse. Scott is known for in-depth financial investigations and deftly handling intra-family dynamics and decades-long family friction. He has extensive experience in courts, arbitration, mediation, and dispute resolution forums across California, as well as in key retirement centers in the United States and through strategic partnerships in international locations.  His clients are typically embroiled in inheritance disputes, trust contests, will contests, caregiver undue influence, step-parent undue influence, sibling undue influence, estate administration irregularities, beneficiary bias, trustee misappropriation, accounting irregularities, breach of fiduciary duty, beneficiary theft, trust investigations, accusations of wrongdoing, fraudulent behavior, wrongful taking something from an estate, and breach of fiduciary duties. He focuses on identifying and correcting where behavior went wrong, and pointing out where allegations of wrongdoing are simply wrong.

Put your eyeballs in the zeros, cuz it is time to partay like it was 2005! The Banter Boys bring you back to the corner of Nostalgia and Reality and dust off some 'new' consoles and franchise starters that released this year with the Resident Evil game. Do you like television or movies that became a video game and railroaded you through the same plot you watched acted out? Then we have a list of games for you! Grab your chair and join us for another Monday at the corner of Nostalgia and Reality with Banter Banter.Intro/Outro:Kong Flix by Voicedbymic on instawebsite: https://blackboxentertainment.ca/Cover art based on work by:Pepper's Socials: https://linktr.ee/peppertroopaBanter on X: https://twitter.com/Banter_CastMike's Socials: https://linktr.ee/meanblazin Manny's Socials: https://linktr.ee/brogarAaron's Socials: VIIIBitWizard on XEmail: banterbantercast@gmail.com

[Recorded on May 14th, 2026]  Dave Cole, CEO of Elemental Royalty Corporation (TSX: ELE) (Nasdaq: ELE), joins me to unpack their news out on May 14th announcing that they have entered into a definitive agreement to acquire all of the issued and outstanding common shares of Vizsla Royalties Corp. (TSX-V: VROY; OTCQX: VROY) by way of a court-approved plan of arrangement.  We also review the Company's Q1 2026 financials and their multiple strategies for continued royalty portfolio grow.   Vizsla Royalties Acquisition Transaction Highlights:   Combination of Vizsla Royalties' silver-gold Panuco royalty with Elemental's high-quality, diversified portfolio creates a platform of cash-flowing and near-term development royalties with long-term growth potential Opportunity to gain exposure to a high-quality royalty over an advanced development project Vizsla Royalties is projected to add approximately 7,500 GEOs[1] per year once in production, providing future revenue uplift as a new cornerstone asset in the Elemental portfolio, and material exposure to silver Life of mine 2.0%-3.5% net smelter returns (“NSR”) royalty, uncapped with no buy-backs or step-downs Substantial exploration upside across a large, under-explored and highly prospective land package Improved trading liquidity and enhanced capital markets profile, further strengthening Elemental as a leading intermediate royalty peer     Q1 2026 Financial Highlights   Record quarterly revenue of US$24.3 million, up 83% over revenue plus attributable share of Caserones in Q1 2025; Gold Equivalent Ounces (“GEOs”) of 4,983 for Q1 2026 (4,606 in Q1 2025), driven by significant contributions from Karlawinda, Bonikro, Timok, and Caserones; Record adjusted EBITDA of US$17.7 million, up 55% over adjusted EBITDA in Q1 2025, reflecting increased operating leverage and portfolio performance; Operating cash flow of US$14.5 million, up 340% over adjusted operating cash flow1 in the comparative period demonstrating strong cash flow conversion; and Cash and cash equivalents as of March 31, 2026of US$69.1 million and working capital of US$92.5 million, demonstrating financial flexibility for growth.   Next, we touched upon some of the key gold and silver cornerstone assets within their royalty portfolio of 18 producing royalties, 30 advanced development assets, and ~200 total mineral royalties globally; diversified across multiple jurisdictions and across precious metals, critical minerals, and battery metals.    Dave points to 4 different approaches to continue to grow future value in Elemental Royalty Corp.  Beyond the organic development growth still on tap within their portfolio of royalties, there is the future upside of their continued royalty generation strategy, the potential for larger future royalty acquisitions and/or royalty financings to create new royalties, and they are always reviewing the potential for accretive M&A opportunities.  The company has plenty of firepower to pursue accretive transactions; with near ~$200Million in combined cash and working capital plus a revolving credit facility, with an accordion feature.   We also discuss the new dividend optionality of being paid in either cash or Tether Gold tokens, (which are backed by physical gold); and the corresponding value of having Tether Investments S.A. de C.V as their key stakeholder.   Dave believes their Company is on the cutting edge of marrying the value of hard assets anchored in commodities and royalty instruments, with the interest from investors in the utility of digital assets.       If you have any follow up questions for Dave or the team at Elemental Royalty Corp, then please email those to me at  Shad@kereport.com.   In full disclosure, Shad is a shareholder of Elemental Royalty Corp at the time of this recording, and may choose to buy or sell shares at any time.   Click to follow the latest news from Elemental Royalty Corp   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned, and companies profiled may be sponsors of the KE Report.  

I've been a full-time creator for 8 years now and have earned $2,192,000 since 2022. I've spent a LOT of time and money experimenting with different ways to make money on the internet, so I'm going to rank them. The best and the worst. I show you 15 different revenue streams and rate them from S to F based on their potential versus the effort required. By the very end of the video, you'll know which ones are right for you. And at any point, if you agree or disagree, let me know in the comments. ⁠⁠⁠⁠⁠⁠⁠⁠Full transcript and show notes⁠⁠⁠⁠⁠⁠⁠⁠ *** TIMESTAMPS (00:32) AdSense (01:36) Sponsorship & Brand Deals (03:30) Content Memberships (04:30) Done-For-You Services (05:27) Royalties (06:28) 1-to-1 Coaching & Consulting (07:38) Affiliates (09:36) User Generated Content (UGC) (10:17) Group Programs (11:25) Digital Products (12:56) Speaking (14:27) Live Events (15:53) Community Memberships *** RECOMMENDED NEXT EPISODE → ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#267: When to use low-ticket offers, refund policies, how much I earned in the last 12 months, and my 5-year vision [Ask CS Pt. 1]⁠ *** ASK CREATOR SCIENCE → ⁠⁠⁠⁠⁠⁠⁠⁠Submit your question here⁠⁠⁠⁠⁠⁠⁠⁠ *** WHEN YOU'RE READY

Most people think buying businesses is a numbers game. Ace Chapman has done 200+ acquisitions - and he'll tell you the numbers are almost never the point. Ace has been in this game since the dot-com bubble. He almost sold a stock market simulator to a little Nebraska company called Omaha Securities - before it became Ameritrade. He got out of a real estate business right before 2008 hit. He's not lucky. He's built a framework for thinking about business ownership that most acquisition guys never arrive at, no matter how many deals they close. But here's where it gets interesting. Right now, while everyone else is hunting online businesses in the U.S., Ace is doing something completely different - buying offline deals in Latin America, where business brokers don't exist and most owners don't even know selling is an option. Hotels. Spas. Mental health clinics. Panama. Colombia. Argentina. He walked into a hotel recently and heard the front desk pitch his own spa to a guest checking in. In this episode, Jaryd sits down with Ace to unpack why he thinks every business is just inventory - and why holding on too long is the real risk most buyers never talk about. How he structures equity deals so he never has to build anything from scratch. And what a real portfolio actually looks like when you stop confusing operating businesses with wealth. Most buyers are waiting for the market to calm down before they make a move. Ace just went and found a completely different market - one where nobody else is even looking.

Send us Fan MailSTOCKS! ANOTHER RECORD. Ownership - Rights - Passive Income.❤️️Grants from states and local governments: https://findhelp.org/❤️️Caregivers, Mental Health: https://www.211.org❤️️Smart Credit helps you control your future credit score. Help Qualify for More. Know your hiring index, credit fraud insurance and so much more. Know who else maybe using your social security number. Interactive and Simple. Signup today for your discount: https://www.smartcredit.com/stopstrugglingnow❤️️Get Your .crypto domain name here. Unstoppable Domains and FREE Minting on Polygon. No Annual Domain Name Fees. Could be the future:

This is wild! Wait until you hear how much the cast of Friends brings home every year in royalties! Even more impressive, Jamie's royalties that she gets for her work on Rockstar!

See omnystudio.com/listener for privacy information.

Send us Fan MailIn this enlightening episode of Living the Dream with Curveball, we welcome Don Rodriguez, a visionary music producer and founder of the iandi Music Studio. Don shares his transformative journey from real estate to the music industry, where he has redefined the traditional record label model to empower independent artists. With a groundbreaking contract that allows artists to retain ownership of their masters and compositions, Don is changing the game for musicians looking to navigate the complexities of today's music landscape.Join us as we delve into the importance of having a record label, the challenges independent artists face in being heard amidst millions of new songs, and the necessity of quality production in achieving musical success. Don explains the unique features of his studio, the value of publishing, and how he is building a catalog of independent artists' music to connect them with opportunities in the entertainment industry. This episode is a must-listen for aspiring musicians and anyone interested in the evolving world of music production.What You'll Learn in This Episode:- The importance of independent artists owning their music- How to navigate the challenges of being heard in a crowded market- The role of a producer in an artist's career- Insights into the music publishing process and why it matters- How Don's innovative contract model benefits artistsSupport the show

In an age where musicians are expected to meticulously audit their music data themselves to ensure money isn't being left on the table, it is inevitable that something will get missed. Notes.FM is designed to lift this weight off of artists' shoulders, having already found missing money for a total of 94% of their users – with the first artist that they claimed money for receiving $75,000 from The MLC. In this episode, Notes.FM founder Tim Luckow discusses his industry journey, goals for the platform, and more!

Michele DeFilippo is the founder and driving force behind 1106 Design, a full-service book publishing company based in Phoenix, Arizona. With more than 50 years of experience in the book publishing industry — spanning traditional publishing, the rise of indie publishing, and the self-publishing revolution catalyzed by Amazon — Michele is one of the most respected voices in author services today.She founded 1106 Design in 2001 after the publishing industry was disrupted by technology, with a singular mission: to help independent authors publish professionally, keep 100% of their rights and royalties, and produce books that compete on equal footing with traditionally published titles. Her company provides a complete "manuscript to market" solution, including editorial evaluations, copyediting, custom book cover design, interior typesetting, eBook conversion, audiobook production, author websites, and publishing support.Michele is also the author of Publish Like the Pros: A Brief Guide to Quality Self-Publishing, an 88-page guide available as a free download at 1106design.com. She has been featured across numerous podcasts, YouTube channels, and industry publications, and contributes regularly to IngramSpark's blog on self-publishing best practices.Schedule a call with Michele today >>WHO IS THIS FOR?Aspiring authors who want to publish without giving up their rights. Self-publishing authors who suspect they're leaving royalty money on the table. Business owners, coaches, and consultants who want a book as a credibility tool. Anyone pitched a "bestseller package" who wants to know if it's legitimate. Podcasters and content creators exploring long-form publishing as a brand extension.Episode SummaryIn this interview on the We Don't PLAY!™ podcast, Favour Obasi-ike, MBA, MS sits down with Michele DeFilippo to unpack one of the most misunderstood and financially consequential decisions an author can make: who to trust with your book. Over 22 minutes, Michele delivers a masterclass on the difference between traditional publishers, hybrid publishers, and true service providers — and why that distinction can mean the difference between earning $0.90 per book sold versus $6–$8.The conversation covers the full publishing landscape: how self-publishing emerged alongside Amazon, why so many "publishers" are actually double-dipping on author revenue, how to use KDP and IngramSpark to distribute without a middleman, what makes a book cover convert (and why it matters more than most authors realize), the truth about Amazon "bestseller" badges, the art of professional typesetting, and how to set realistic expectations before publishing.Michele closes with a transparent overview of how 1106 Design works, what authors should prepare before reaching out, and why the best way to make money with a book is often not through retail sales at all.TIMESTAMPS[00:00] — Intro: Michele DeFilippo, founder of 1106 Design, 50 years in publishing[03:20] — Publisher vs. service provider: the distinction that determines your royalties[06:12] — The hybrid publisher double-dip: earning $0.90/book instead of $6–$8[09:11] — KDP and IngramSpark: the two platforms every self-publishing author must know[10:01] — "Pump and dump" publishing: the automated book trap[11:00] — Book covers as the #1 conversion driver: the job interview analogy[12:48] — A/B testing covers the right way: "liking vs. buying"[14:34] — The Amazon bestseller badge: how it's manufactured in 45 minutes[17:08] — Professional typesetting vs. basic formatting: why it matters[20:49] — Using a book as a business development tool, not a retail productMEMORABLE QUOTES"If you have no investment in my book, what entitles you to any portion of my profits?" — Michele [06:45]"There's retail sales, and then there's making money with your book another way — and that other way is usually better." — Michele [20:49]"The question isn't which cover do you like. It's which cover would you spend money on." — Michele [12:48]"A book that earns $2,000 in royalties but generates $50,000 in consulting revenue is not a modest success. It's a high-ROI asset." — Favour [21:10]"Typesetting is working on every line, every word, every paragraph — it's not just formatting." — Michele [17:08]FAQsWhat is the difference between a publisher and a service provider?A publisher acquires your rights and pays a royalty. A service provider charges once and steps away — you keep 100% of all future revenue.What makes hybrid publishers problematic?They charge upfront fees and also take a cut of every book sold — reducing per-book earnings from $6–$8 down to $0.90 on a $19.99 title.Which platforms should every author use?KDP for Amazon and IngramSpark for bookstores and libraries. Both have royalty calculators so you know exactly what you'll earn.Are Amazon bestseller badges legitimate?Most are manufactured in 45 minutes by selecting a low-competition subcategory. A genuine Nielsen bestseller is an entirely different credential.How do authors actually make money with a book?Treat it as a business development tool. Speaking fees and consulting revenue typically far exceed retail royalty income.GLOSSARYService Provider — Charges a one-time fee; takes no ongoing royalties. The author retains 100% of rights and revenue.Hybrid Publisher — Charges upfront fees and also takes a percentage of sales. Double-dips on author revenue.KDP — Amazon's self-publishing platform for print-on-demand paperbacks and Kindle ebooks.IngramSpark — Distributes to independent bookstores, libraries, and international retailers.Typesetting — Professional design of a book's interior: fonts, spacing, margins, and chapter breaks.Print-on-Demand — Books printed individually as orders are placed. No inventory risk.Ready to Rank? Book Your SEO & Web Dev Services Today

Versamet Royalties has announced the acquisition of a 3.52% life-of-mine gold stream on Skeena Resources' Eskay Creek project in British Columbia. Gold X2 Mining has announced a new Superion Shear discovery at its Moss Gold Project in northwestern Ontario. Liberty Gold has announced a significant permitting milestone at its Black Pine Oxide Gold Project in southeastern Idaho. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Stoked to have Will back on the podcast to discuss: Clean Tech Royalty companies (like CVW) Copper producersGold producersWill's Commodity Purity Index (or CPI) Using AI in investment researchGoing slow to go fast (read before summarizing)Really liked this chat. NOTHING YOU HEAR IS INVESTMENT ADVICE. PURELY ENTERTAINMENT PURPOSES. YOU ARE A FOOL IF YOU THINK ANY OF THIS IS ADVICE. DO YOUR OWN WORK.

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

Tim Conway Jr. Show Hour 1 (3.16) Mark Thompson in the house tonight! With special studio guest Charlie Fox! Tim Conway Jr has known Charlie since he was 12 years old. He’s an amazing Hollywood composer who’s written the best TV theme songs and movie soundtracks, plus the soundtrack to your life. Think Laverne & Shirley, Happy Days, The Love Boat, “Killing Me Softly.” To more with Charlie Fox, arguably the world’s greatest composer! He’s got some stories to tell about Hollywood in the ’60s, ’70s and ’80s — and you best believe we’re all ears for the man with the best ear in Tinseltown. If you’re off key, Charlie’s gonna notice. Wanna hear Tim Conway Jr. perform a 1980s rap in the manner of Ice-T but produced by Charlie Fox? Well you’ve come to the right podcast! We finish off with Charlie Fox by talking about his first album in 50 years, a salsa record! Plus hear about his favorite place to visit in Beverly Glen.See omnystudio.com/listener for privacy information.

Summit Royalties has put its claims in the royalty space over the past week with two new deals. First, the company acquired a royalty on Newmont's Saddle North Deposit in BC, which provides some optionality within the company's portfolio of assets. But Summit then turned around earlier this week and announced the acquisition of Star Royalties in an all-share deal, which would bring in their entire portfolio of assets as well.

Summit Royalties and Star Royalties are combining. Summit has agreed to acquire all of the issued and outstanding common shares of Star. We have new drill results out from Souther Cross Gold and Banyan Gold. Great Pacific has new exploration news out. American Pacific will begin the MT Survey over Madison. Eldorado Gold has received its Operating Authorization for the Ormaque deposits at the Lamaque Complex in Val-d'Or, Quebec. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Jim Edwards breaks down his most profitable use of writing a book. It is not book royalties, though those are nice. The biggest gains in revenue from writing a book come from a wide variety of uses of the book as leverage to sell higher-priced items in your business. Things like coaching programs, courses, and membership programs are bigger ticket items you can and should use your book to leverage. Check out more of Jim Edwards coaching and software programs for content marketing and sales copywriting at https://www.copyandcontent.ai. Save time and make money using the programs and his coaching. 

On today's episode, Dr. Mark Costes sits down with Nathan Raborn, a senior wealth manager at Eckard Enterprises who brings a unique perspective on alternative investments after spending over a decade in the oil and gas sector at ExxonMobil. Nathan shares how he transitioned from managing short-term and mid-term rental properties to focusing almost entirely on mineral rights and working interest investments. He explains why real estate wasn't delivering the cash flow he expected, and how oil and gas opened up new possibilities for passive income, portfolio diversification, and significant tax advantages.  You'll hear a clear breakdown of mineral rights vs. working interests, real-world returns, tax strategies (including Roth conversions and 1031 exchanges), and how Eckard differentiates itself in a space often filled with bad actors. This is a must-listen for high-income earners looking to keep more of what they earn and grow wealth through alternative channels. Be sure to check out the full episode from the Dentalpreneur Podcast! EPISODE RESOURCES https://eckardenterprises.com https://www.truedentalsuccess.com Dental Success Network Subscribe to The Dentalpreneur Podcast

Roxanne Shanté Speaks Out: Roxanne Roxanne 2, Tears, Rap Battles & Lost Royalties + More See omnystudio.com/listener for privacy information.

On this episode of 83 Weeks, Eric Bischoff and Conrad Thompson take a deep dive into WWE's so-called royalty system. Eric weighs in on a recent social media post from Marc Mero that reignited the debate, offering his candid take on how things really work behind the scenes. The guys also break down the fallout from TNA's debut on AMC, including the disappointing ratings and reports of interest from a major hip-hop artist looking to buy the company. Plus, has WWE Unreal officially gone off the rails? Eric and Conrad share their unfiltered thoughts on Season Two of the Netflix series. It's a news-heavy, opinionated edition of 83 Weeks you won't want to miss. HARRY'S PLUS - Get the Harry's Plus Trial Set for only $10 at https://harrys.com/83WEEKS #Harryspod MARS MEN - Get 50% off FOR LIFE, Free Shipping AND 3 Free Gifts at Mars Men at http://Mengotomars.com  CHIME - Chime is not just smarter banking, it is the most rewarding way to bank. Join the millions who are already banking fee free today. It just takes a few minutes to sign up. Head to http://Chime.com/83WEEKS  . SIGNOS - Visit http://SIGNOS.com  and get 25% off select plans with code 83WEEKS.  STEVEN SINGER JEWELERS - No one does real diamond jewelry better. Experience the difference at Steven Singer Jewelers. Go online to http://IHateStevenSinger.com  today! Always fast and FREE shipping is waiting for you. BLUECHEW - Get 10% off your first month of BlueChew Gold with code 83WEEKS at http://BlueChew.com  PRIZE PICKS - Visit https://prizepicks.onelink.me/LME0/83WEEKS  and use code 83WEEKS to get $50 in lineups after you pay your first $5 lineup! SAVE WITH CONRAD - Stop throwing money away by paying those high interest rates on your credit card. Roll them into one low monthly payment and on top of that, skip your next two house payments. Go to https://www.savewithconrad.com  to learn more.

An independent musician seeks advice on skipping out on Spotify. Royalties for most artists are dismal on streaming services—is corporate licensing for background music a better option? Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com Read A Year of Mental Health: yearofmentalhealth.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.